LAVAL, Quebec, Feb. 28, 2011 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) and Acasti Pharma ("Acasti"), a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares (the "Class A shares") on the TSX Venture Exchange (the "Exchange") under the ticker symbol APO. Acasti has received conditional approval from the Exchange for the listing of its Class A share on the TSX-Venture (the "Listing"). The Listing is conditional, to fulfilment by Acasti of all Exchange's requirements including, among others: (i) the conversion of all outstanding Class B and Class C preferred shares into Class A shares on a 1:1 basis, (ii) the signature of an escrow agreement between Acasti, the escrow agent and Acasti's principal securities holders, (iii) the filing of amended and restated financial statements for the three and nine-month periods ended November 30 th, 2010 reflecting, among others, subsequent events in connection with the Listing, and (iv) the completion of satisfactory background searches on Acasti's insiders. Acasti's management expects to waive all conditions with respect to the Listing prior to March 21, 2011. A complete press release will be issued by Acasti and Neptune at the time of the Listing, providing summary disclosure of the Listing and any related transaction. About Neptune Technologies & Bioressources Inc. Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.